JP2021504420A5 - - Google Patents

Download PDF

Info

Publication number
JP2021504420A5
JP2021504420A5 JP2020529534A JP2020529534A JP2021504420A5 JP 2021504420 A5 JP2021504420 A5 JP 2021504420A5 JP 2020529534 A JP2020529534 A JP 2020529534A JP 2020529534 A JP2020529534 A JP 2020529534A JP 2021504420 A5 JP2021504420 A5 JP 2021504420A5
Authority
JP
Japan
Prior art keywords
synthetic composition
hmo
human
gastrointestinal
human milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/059501 external-priority patent/WO2019106620A1/en
Publication of JP2021504420A publication Critical patent/JP2021504420A/ja
Publication of JP2021504420A5 publication Critical patent/JP2021504420A5/ja
Pending legal-status Critical Current

Links

JP2020529534A 2017-11-30 2018-11-30 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物 Pending JP2021504420A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201700680 2017-11-30
DKPA201700680 2017-11-30
DKPA201700690 2017-12-05
DKPA201700690 2017-12-05
PCT/IB2018/059501 WO2019106620A1 (en) 2017-11-30 2018-11-30 Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation

Publications (2)

Publication Number Publication Date
JP2021504420A JP2021504420A (ja) 2021-02-15
JP2021504420A5 true JP2021504420A5 (cg-RX-API-DMAC7.html) 2022-01-06

Family

ID=66664406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529534A Pending JP2021504420A (ja) 2017-11-30 2018-11-30 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物

Country Status (7)

Country Link
US (1) US20200323921A1 (cg-RX-API-DMAC7.html)
EP (1) EP3716983A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021504420A (cg-RX-API-DMAC7.html)
KR (1) KR102741265B1 (cg-RX-API-DMAC7.html)
CN (1) CN111683665A (cg-RX-API-DMAC7.html)
BR (1) BR112020010843A2 (cg-RX-API-DMAC7.html)
WO (1) WO2019106620A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
JP2022513524A (ja) 2018-12-19 2022-02-08 グリコム・アクティーゼルスカブ 低fodmap食を使用してヒトを治療するための組成物および方法
US20220054515A1 (en) * 2018-12-21 2022-02-24 Glycom A/S Composition and method for promoting intestinal barrier healing
EP3980025A4 (en) * 2019-06-05 2023-06-14 Glycom A/S HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-CELIAC GLUTEN AND/OR WHEAT SENSITIVITY
AU2020354581A1 (en) * 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
WO2021094993A1 (en) * 2019-11-14 2021-05-20 Glycom A/S Synthetic composition for balancing the bile acid profile in the intestine
US11331329B2 (en) 2020-05-13 2022-05-17 Glycosyn LLC Fucosylated oligosaccharides for prevention of coronavirus infection
EP4149482A4 (en) 2020-05-13 2024-05-22 Glycosyn LLC 2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION
US11896603B2 (en) * 2020-06-12 2024-02-13 The Regents Of The University Of California Oligosaccharide as therapeutic agent for alcohol associated liver disease
JP2023536090A (ja) * 2020-07-31 2023-08-23 アボット・ラボラトリーズ 脂肪肝疾患を予防、低減または遅延させる方法
WO2022117829A1 (en) * 2020-12-04 2022-06-09 Société des Produits Nestlé S.A. Compositions comprising human milk oligosaccharides for use in a subject to support night sleep duration
KR102456307B1 (ko) * 2021-11-10 2022-10-19 충남대학교산학협력단 3’-시알릴락토오스, 6’-시알릴락토오스 또는 이의 염을 유효성분으로 포함하는 감염에 의한 다발성 장기부전의 예방 또는 치료용 조성물
JP2023096870A (ja) * 2021-12-27 2023-07-07 株式会社明治 アッカーマンシア属細菌の増殖促進剤
US20260165955A1 (en) 2022-03-18 2026-06-18 Meiji Co., Ltd. Composition for controlling growth of bacteria of the genus collinsella and use thereof
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation
CN119138609B (zh) * 2024-11-19 2025-02-25 飞鹤(吉林)乳品有限公司 母乳低聚糖改善母婴肠道菌群的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055944A2 (en) * 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
EP2439264B1 (en) * 2010-10-11 2015-06-03 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
MX356184B (es) * 2010-12-31 2018-05-17 Abbott Lab Fórmulación pediátrica sintética que comprende un probiótico.
AU2012215042B2 (en) * 2011-02-10 2016-01-14 Société des Produits Nestlé S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用
NL2007268C2 (en) * 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
US10639319B2 (en) * 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MX2014012362A (es) * 2012-04-13 2015-05-07 Trustees Boston College Composición prebiótica y métodos de uso.
EP2842560A4 (en) * 2012-04-23 2015-12-02 Univ Kyoto COMPOSITION TO PROMOTE THE GROWTH OF BIFIDOBAKTERIA
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
CN107108677B (zh) * 2014-10-24 2020-08-07 格礼卡姆股份公司 Hmo的混合物
US20170258820A1 (en) * 2014-10-29 2017-09-14 Glycom A/S Synthetic composition and method for promoting mucosal healing
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10881674B2 (en) * 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
MX378680B (es) * 2015-03-05 2025-03-11 Soc Des Produits Nestle S A Star Composiciones para usar en la prevencion o el tratamiento de infecciones/inflamaciones gastrointestinales en infantes o niños pequeños.
ES2886951T3 (es) * 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota
US10537597B2 (en) * 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
CN108471793A (zh) * 2016-01-26 2018-08-31 雀巢产品技术援助有限公司 用于婴儿或幼儿以预防或治疗变态反应的包含人乳低聚糖的组合物
EP3589139A4 (en) * 2017-03-01 2020-12-23 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
WO2018207110A1 (en) * 2017-05-09 2018-11-15 Glycom A/S Synthetic composition for microbiota modulation
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
US11541068B2 (en) * 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
EP3743078A4 (en) * 2017-12-22 2022-01-19 Glycom A/S COMPOSITION WITH HMOs TO PREVENT OR REDUCE NOCICEPTION

Similar Documents

Publication Publication Date Title
Weber et al. Dietary fiber mixture in pediatric patients with controlled chronic constipation
JP2017533915A5 (cg-RX-API-DMAC7.html)
JP2014528474A5 (cg-RX-API-DMAC7.html)
JP2021504421A5 (cg-RX-API-DMAC7.html)
CN105106245A (zh) Akkermansia muciniphila BAA-835菌株的应用
EP4255443A1 (en) Stable semi-solid chewable gel compositions and methods of making and using thereof
CN101686995A (zh) Hiv患者肠内菌群的调节
JP2020178685A (ja) 腸管障害の予防、治療又は抑制用組成物
Serra et al. Prebiotic intake in older adults: effects on brain function and behavior
CN103648504A (zh) 用于预防或减小发生代谢综合征的风险的低聚糖组合物
Patil A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate & severe grade with only Ayurvedic Medicines
CN110448569B (zh) 一种具有止泻功效的组合物及其制备方法和其应用
Mehjabin et al. Role of inulin in the management of metabolic disorders
US8840938B2 (en) Bioavailability enhancing composition
CN116568312A (zh) 稳定的半固体可咀嚼凝胶组合物及其制作和使用方法
CN108653298A (zh) 单糖组合物、药物制剂及其应用
WO2023284778A1 (zh) 一种益生元组合物及其应用
CN105451749B (zh) 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用
JP2009013173A (ja) いびき抑制剤
US20240358782A1 (en) Regulatory Composition of the Neuro-Immune-Endocrine and Cortisol Reducing System of the Human Being
JP6940265B2 (ja) 止瀉剤組成物
JP2018522031A (ja) 副鼻腔炎に対するイヌリンの予防的使用
Shapiro et al. An evidence-based narrative review of oral supplements for the treatment of patients with irritable bowel syndrome
US3150043A (en) Anorectic composition
JP4221266B2 (ja) アレルギー性疾患の症状を抑制・緩和するための薬剤